Home
Athenex

Athenex Market Share Analysis for May 2026

a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer.

Health > Biotechnology and Pharmaceuticals

Domainathenex.com

Year Founded2003

Employees201 - 500

Annual Revenue$100M - $200M

Athenex

Athenex (including company regionals)

athenex.com

See more website traffic and engagement information

Athenex Revenue up to May 2026 is 100M - 200M

revenue generated by Athenex top domains

Athenex top domains revenue over 3 years

Revenue for Athenex top domains

athenex.com100M - 200M

See more with Sales Intelligence

Total visits to Athenex's top domains

Understand Athenex market share and potential market reach.

Total visits last 3 months

No Data to Display

Avg. visit duration in Athenex's top domains

Analyze Athenex engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on Athenex's top domains

See how Athenex keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

No Data to Display

Athenex top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Athenex

These are the website technologies, by industry, used by Athenex top domains

Widget (5)

Twemoji

Email Services (3)

G Suite

Content Management System (2)

WordPress

Conversion & Analytics (2)

Google Analytics

More Technologies

5

See all

News & Signals from Athenex

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsAthenex sold assets to Sagent Pharmaceuticals on Jun 1st '23.Schaumburg, Illinois-based Sagent Pharmaceuticals purchased assets from Athenex Pharmaceutical Division in a deal that closed June 30, according to the SEC filing.

NewsAthenex closed offices in New York, New York, United States, Northern America, Americas on Aug 10th '23.Athenex (Nasdaq: ATNX) will close both its locations — in the Conventus Building on Main Street in Buffalo and at 11342 Main St. facility in Clarence — by Aug. 10.

NewsHangauer retired from Athenex as chief scientific officer on Dec 1st '16.While Hangauer retired from Athenex in December 2016 as chief scientific officer, he remembers the buzz around the company back then.